(Q35808427)

10 August 2017

Design issues in randomized phase II/III trials (English)

1 reference

10 August 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

2

Boris Freidlin

1 reference

10 August 2017

Edward L Korn

1

1 reference

10 August 2017

Jeffrey S Abrams

series ordinal

3

1 reference

10 August 2017

Susan Halabi

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

23 January 2012

1 reference

Journal of Clinical Oncology

10 August 2017

1 reference

10 August 2017

30

1 reference

10 August 2017

6

1 reference

10 August 2017

667-671

1 reference

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Bevacizumab and everolimus in renal cancer: a rational way forward

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Seamless phase II/III designs

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

A comparison of phase II study strategies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Monitoring for lack of benefit: a critical component of a randomized clinical trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Speeding up the evaluation of new agents in cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Multi-arm clinical trials of new agents: some design considerations

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Interim futility analysis with intermediate endpoints

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Design issues of randomized phase II trials and a proposal for phase II screening trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Clinical trial designs for cytostatic agents: are new approaches needed?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Optimal two-stage designs for phase II clinical trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Adaptive methods: telling "the rest of the story".

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

A general inefficacy interim monitoring rule for randomized clinical trials

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295562

Picking the winners in a sea of plenty

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22271475

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase II clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22271475

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2011.38.5732

1 reference

OpenCitations bibliographic resource ID

10 August 2017

0 references

1 reference

10 August 2017

PubMed publication ID

22271475

1 reference